ALPMF

Healthcare Drug Manufacturers - General

Astellas Pharma Inc.

$14.37

-0.30 -2.04% today

Price History

Not enough data

Key Stats

Market Cap

25.77B

Avg Volume

5,540

P/E (TTM)

13.95

EPS

$1.03

52W High

$17.85

52W Low

$9.85

Div. Yield

531.7%

Valuation

Forward P/E

32.66

P/B Ratio

2.09

P/S Ratio

0.01

EV/EBITDA

0.56

EV/Revenue

0.16

Margins

Gross Margin 80.8%

Operating Margin 28.9%

Net Margin 16.0%

EBITDA Margin 29.4%

Growth & Returns

Revenue Growth (YoY)

26.7%

Earnings Growth (YoY)

107.2%

Earnings Growth (QoQ)

107.3%

Return on Equity

21.3%

Return on Assets

8.4%

Liquidity & Leverage

Current Ratio

1.20

Quick Ratio

0.88

Debt / Equity

0.30

Total Cash

244.70B

Total Debt

589.87B

About

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.